Blog
RSS FeedPosted by Michael Wonder on 29 Jan 2018
Roche haemophilia drug lowers costs despite high price: ICER
27 January 2018 - A costly new Roche Holding AG drug to treat the bleeding disorder haemophilia A could significantly reduce ...
Posted by Michael Wonder on 26 Jan 2018
Institute for Clinical and Economic Review releases draft evidence report on emicizumab for haemophilia A
26 January 2018 - Public comment period now open until 23 February 23; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 13 Jan 2018
Institute for Clinical and Economic Review Report on voretigene neparvovec suggests substantial price discount needed to meet traditional cost-effectiveness standards
12 January 2018 - Special considerations include patient age, benefit durability, and rarity of condition. ...
Posted by Michael Wonder on 11 Jan 2018
Institute for Clinical and Economic Review posts draft scoping document on elagolix for endometriosis
11 January 2018 - Document open to public comment until 1 February 2018. ...
Posted by Michael Wonder on 06 Jan 2018
Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences
26 December 2018 - Patient preferences should be a central consideration in healthcare decision making. ...
Posted by Michael Wonder on 29 Dec 2017
ICER’s guideline on the acceptance and use of “in-confidence” data from manufacturers of pharmaceuticals, devices, and other health care interventions
22 December 2017 - ICER takes its obligations to transparency and fairness seriously. ...
Posted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ...
Posted by Michael Wonder on 20 Dec 2017
Institute for Clinical and Economic Review releases draft evidence report on CAR-T therapy for B-cell cancers
19 December 2017 - Public comment period open now until 24 January; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 15 Dec 2017
Institute for Clinical and Economic Review to assess elagolix for management of endometriosis
14 December 2017 - Open input now being accepted until 8 January 2018. ...
Posted by Michael Wonder on 05 Dec 2017
Institute for Clinical and Economic Review posts draft scoping documents for two reviews: CGRP inhibitors for migraine and update to prior review of plaque psoriasis treatments
4 December 2017 - Documents open to public comment until 22 December 2017. ...
Posted by Michael Wonder on 22 Nov 2017
Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patient
21 November 2017 - Report will be subject to public deliberation during New England CEPAC meeting on 5 December 2017. ...
Posted by Michael Wonder on 14 Nov 2017
Institute for Clinical and Economic Review releases draft evidence report on voretigene neparvovec, gene therapy for blindness
14 November 2017 - Public comment period now open until 13 December; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 13 Nov 2017
Institute for Clinical and Economic Review announces final modified framework for assessing value of treatments for ultra rare diseases
13 November 2017 - Broader societal considerations and expanded cost-effectiveness ranges will be included for treatments targeting fewer than 10,000 patients. ...
Posted by Michael Wonder on 10 Nov 2017
Institute for Clinical and Economic Review to assess erenumab for migraine prevention; guselkumab and tildrakizumab for plaque psoriasis
9 November 2017 - Open Input now being accepted on both topics; both reviews to be subject to public deliberation at ...
Posted by Michael Wonder on 06 Nov 2017
Institute for Clinical and Economic Review final report recommends enhanced coverage of certain non-drug management options for chronic low back pain
6 November 2017 - Evidence suggests safe and effective treatments include acupuncture, cognitive behavioral therapy, mindfulness-based stress reduction, and yoga. ...